SUBSCRIBE NOW Just 99¢ for your first month

ADVERTISEMENT

ADVERTISEMENT

Essentia joins national COVID-19 medication study

The ACTIV-6 clinical trial will include the study of fluticasone, fluvoxamine and ivermectin to treat mild to moderate COVID infection.

Aerial photo of Essentia Health's downtown Duluth campus
Essentia Health in Duluth as seen in July 2020.
File / Duluth News Tribune
We are part of The Trust Project.

DULUTH — Essentia Health has joined a nationwide COVID-19 treatment study evaluating repurposed medications, the health care system announced Monday morning in a news release.

The ACTIV-6 (Accelerating COVID Therapeutic Interventions and Vaccines) clinical trial will include the study of fluticasone, an inhaled steroid commonly prescribed for asthma and chronic obstructive pulmonary disease; fluvoxamine, a selective serotonin re-uptake inhibitor (SSRI), often prescribed for depression; and ivermectin, used to treat parasitic infections.

The medications are already approved by the Food and Drug Administration and considered to be safe and effective for treating other medical diagnoses.

“If enough people diagnosed with COVID-19 participate in this study, we can answer quickly whether these medications will be beneficial in treating mild-to-moderate COVID," Rajesh Prabhu, an infectious disease physician at Essentia, said in the news release. "The aim of the study is to see if these medications make you feel better sooner and prevent hospitalization.”

Participants can choose to participate in one of the drug's studies, and will be randomly assigned either the medication or a placebo to take for the treatment time of three, 10 or 14 days, depending on the medication. Their symptoms and recovery will be tracked through online surveys over a span of 90 days.

ADVERTISEMENT

READ MORE ABOUT COVID-19
The Centers for Disease Control and Prevention recommends isolating COVID patients for at least five days, preferably in a separate room with access to their own bathroom, as well as diligent mask-wearing for both patient and caregiver. But for many families, those aren’t easy options. But take heart: Scientists say there is still a lot people can do to protect their families, chief among them improving ventilation and filtration of the air.

To participate in the trial, candidates must be age 30 or older and have tested positive for COVID within the past 10 days. Participants must have at least two of the following COVID symptoms within the last seven days: fatigue, difficulty breathing, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms and/or new loss of taste or smell.

Currently, there are two oral prescription medications that have received emergency use authorization from the FDA. Paxlovid and molnupiravir are only available to individuals considered at higher risk for developing severe COVID infection, but do not require hospitalization. Prabhu said the goal of the ACTIV-6 study is to find treatment for mild to moderate cases of COVID to decrease infection severity and recovery time.

Prabhu said the three medications in the trial were selected because of previous evidence in small COVID treatment studies for their anti-inflammatory properties. Researchers will monitor whether the medications actually do benefit COVID patients.

"There have been small studies that suggest potential benefit, and the purpose of ACTIV-6 as a nationwide study is to enroll 15,000 people," Prabhu said. "The more people you study, the more certainty you have if the medication works or not."

The study, funded by the National Institutes of Health, is led by researchers from Duke Clinical Research Institute and Vanderbilt University Medical Center. It is part of the ACTIV, led by the National Center for Advancing Translational Sciences.

The medications are shipped at no cost to participants. The double-blind study does not require any site visits, therefore, anyone in the United States can participate through web- and phone-based enrollment. Essentia is one of many centers across the country helping facilitate the trials. Participants can receive $100 for completing the study.

To enroll with ACTIV-6, visit activ6study.org or call 833-385-1880. Potential participants also can call Essentia Health at 866-839-4128 or visit essentiahealth.org .

Laura Butterbrodt covers health and business for the Duluth News Tribune. She has a bachelor of arts in journalism from South Dakota State University and has been working as a reporter in Minnesota and South Dakota since 2014.
What to read next
If signed into law by the governor, the legislation would prohibit life insurance, long-term care insurance or disability insurance carriers from declining or limiting coverage to living organ or marrow donors.
When you have one of those mornings that starts in a frenzy and throws you off your game, you might feel a little off kilter the rest of the day. Those episodes can quickly derail a fitness and healthy eating plan. In this "Health Fusion" column, the Goal Getters Project shares a great tip that may help keep you on track in the morning so you can have a successful day.
Don't be afraid to create a DIY container garden full of flowers. There are no rules! Whatever plants you pick will help brighten your days and lift your mood. In this episode of NewsMD's "Health Fusion," Viv Williams shares three tips for a stunning pot of flowers.
The free webinar is hosted in partnership with the American Heart Association.